Optic Neuritis

Ophthalmology
6
Pipeline Programs
8
Companies
5
Clinical Trials
2 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
1
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

Teva
COPAXONEApproved
glatiramer acetate
Teva
subcutaneous1996
U
GLATIRAMER ACETATEApproved
glatiramer acetate
Unknown Company
subcutaneous2024

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
1
1
Glatiramer AcetatePhase 31 trial
Active Trials
NCT00856635Completed44Est. Feb 2011
argenx
argenxBelgium - Zwijnaarde
1 program
1
Efgartigimod AlfaPhase 21 trial
Active Trials
NCT06453694Recruiting20Est. Jul 2027
O
OculisZUG, Switzerland
1 program
1
OCS-05 +SoCPhase 21 trial
Active Trials
NCT04762017CompletedEst. Sep 2024
Accure Therapeutics
Accure TherapeuticsSpain - Barcelona
1 program
1
Comparison of BN201 treatment with PlaceboPhase 11 trial
Active Trials
NCT03630497Completed48Est. Feb 2019
Roche
RocheSTAVANGER NORWAY, Norway
1 program
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)N/A
Sanofi
SanofiPARIS, France
1 program
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)N/A
Biogen
BiogenCAMBRIDGE, MA
1 program
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)N/A1 trial
Active Trials
NCT05017142Recruiting500Est. Jan 2071
Novartis
NovartisBASEL, Switzerland
1 program
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)N/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TevaGlatiramer Acetate
argenxEfgartigimod Alfa
OculisOCS-05 +SoC
Accure TherapeuticsComparison of BN201 treatment with Placebo
BiogenSwiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Clinical Trials (5)

Total enrollment: 612 patients across 5 trials

NCT00856635TevaGlatiramer Acetate

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Start: Feb 2009Est. completion: Feb 201144 patients
Phase 3Completed
NCT06453694argenxEfgartigimod Alfa

Efgartigimod for the Treatment of Acute Optic Neuritis

Start: Aug 2025Est. completion: Jul 202720 patients
Phase 2Recruiting
NCT04762017OculisOCS-05 +SoC

OCS-05 in Patients With Optic Neuritis

Start: Feb 2021Est. completion: Sep 2024
Phase 2Completed
NCT03630497Accure TherapeuticsComparison of BN201 treatment with Placebo

BN201 SAD MAD Study in Healthy Subjects

Start: May 2018Est. completion: Feb 201948 patients
Phase 1Completed
NCT05017142BiogenSwiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Start: Apr 2020Est. completion: Jan 2071500 patients
N/ARecruiting

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 612 patients
8 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)